VERTEX PHARMACEUTICALS INC / MA Quarterly Common Stock, Shares Authorized from Q1 2010 to Q3 2024

Taxonomy & unit
us-gaap: shares
Description
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Summary
Vertex Pharmaceuticals Inc / Ma quarterly Common Stock, Shares Authorized history and growth rate from Q1 2010 to Q3 2024.
  • Vertex Pharmaceuticals Inc / Ma Common Stock, Shares Authorized for the quarter ending September 30, 2024 was 500M shares, unchanged year-over-year.
Common Stock, Shares Authorized, Quarterly (shares)
Common Stock, Shares Authorized, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 500M 0 0% Sep 30, 2024 10-Q 2024-11-05
Q2 2024 500M 0 0% Jun 30, 2024 10-Q 2024-08-02
Q1 2024 500M 0 0% Mar 31, 2024 10-Q 2024-05-07
Q4 2023 500M 0 0% Dec 31, 2023 10-Q 2024-11-05
Q3 2023 500M 0 0% Sep 30, 2023 10-Q 2023-11-07
Q2 2023 500M 0 0% Jun 30, 2023 10-Q 2023-08-02
Q1 2023 500M 0 0% Mar 31, 2023 10-Q 2023-05-02
Q4 2022 500M 0 0% Dec 31, 2022 10-K 2024-02-15
Q3 2022 500M 0 0% Sep 30, 2022 10-Q 2022-10-28
Q2 2022 500M 0 0% Jun 30, 2022 10-Q 2022-08-05
Q1 2022 500M 0 0% Mar 31, 2022 10-Q 2022-05-06
Q4 2021 500M 0 0% Dec 31, 2021 10-K 2023-02-10
Q3 2021 500M 0 0% Sep 30, 2021 10-Q 2021-11-03
Q2 2021 500M 0 0% Jun 30, 2021 10-Q 2021-07-30
Q1 2021 500M 0 0% Mar 31, 2021 10-Q 2021-04-30
Q4 2020 500M 0 0% Dec 31, 2020 10-K 2022-02-09
Q3 2020 500M 0 0% Sep 30, 2020 10-Q 2020-10-30
Q2 2020 500M 0 0% Jun 30, 2020 10-Q 2020-07-31
Q1 2020 500M 0 0% Mar 31, 2020 10-Q 2020-05-01
Q4 2019 500M 0 0% Dec 31, 2019 10-K 2021-02-11
Q3 2019 500M 0 0% Sep 30, 2019 10-Q 2019-10-31
Q2 2019 500M 0 0% Jun 30, 2019 10-Q 2019-08-01
Q1 2019 500M 0 0% Mar 31, 2019 10-Q 2019-05-01
Q4 2018 500M 0 0% Dec 31, 2018 10-K 2020-02-13
Q3 2018 500M 0 0% Sep 30, 2018 10-Q 2018-10-25
Q2 2018 500M 0 0% Jun 30, 2018 10-Q 2018-07-26
Q1 2018 500M 0 0% Mar 31, 2018 10-Q 2018-04-27
Q4 2017 500M 0 0% Dec 31, 2017 10-K 2019-02-13
Q3 2017 500M 0 0% Sep 30, 2017 10-Q 2017-10-30
Q2 2017 500M 0 0% Jun 30, 2017 10-Q 2017-07-28
Q1 2017 500M 0 0% Mar 31, 2017 10-Q 2017-04-28
Q4 2016 500M 0 0% Dec 31, 2016 10-K 2018-02-15
Q3 2016 500M 0 0% Sep 30, 2016 10-Q 2016-10-31
Q2 2016 500M 0 0% Jun 30, 2016 10-Q 2016-08-01
Q1 2016 500M +200M +66.7% Mar 31, 2016 10-Q 2016-05-03
Q4 2015 500M +200M +66.7% Dec 31, 2015 10-K 2017-02-23
Q3 2015 500M +200M +66.7% Sep 30, 2015 10-Q 2015-10-30
Q2 2015 500M +200M +66.7% Jun 30, 2015 10-Q 2015-08-04
Q1 2015 300M 0 0% Mar 31, 2015 10-Q 2015-05-04
Q4 2014 300M 0 0% Dec 31, 2014 10-K 2016-02-16
Q3 2014 300M 0 0% Sep 30, 2014 10-Q 2014-11-06
Q2 2014 300M Jun 30, 2014 10-Q 2014-07-31
Q1 2014 300M 0 0% Mar 31, 2014 10-Q 2014-05-05
Q4 2013 300M 0 0% Dec 31, 2013 10-K 2015-02-13
Q3 2013 300M 0 0% Sep 30, 2013 10-Q 2013-11-07
Q1 2013 300M 0 0% Mar 31, 2013 10-Q 2013-05-08
Q4 2012 300M 0 0% Dec 31, 2012 10-K 2014-02-11
Q3 2012 300M 0 0% Sep 30, 2012 10-Q 2012-11-06
Q2 2012 300M 0 0% Jun 30, 2012 10-Q 2012-08-08
Q1 2012 300M 0 0% Mar 31, 2012 10-Q 2012-05-10
Q4 2011 300M 0 0% Dec 31, 2011 10-K 2013-03-01
Q3 2011 300M 0 0% Sep 30, 2011 10-Q 2011-11-03
Q2 2011 300M 0 0% Jun 30, 2011 10-Q 2011-08-09
Q1 2011 300M 0 0% Mar 31, 2011 10-Q 2011-05-06
Q4 2010 300M Dec 31, 2010 10-K 2012-02-22
Q3 2010 300M Sep 30, 2010 10-Q 2010-10-28
Q2 2010 300M Jun 30, 2010 10-Q 2010-08-03
Q1 2010 300M Mar 31, 2010 10-Q 2010-05-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.